You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

~ Buy the CAPLYTA (lumateperone tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR CAPLYTA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CAPLYTA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05356013 ↗ Caplyta in Borderline Personality Disorder Not yet recruiting Intra-Cellular Therapies, Inc. Phase 2 2022-07-01 The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
NCT05356013 ↗ Caplyta in Borderline Personality Disorder Not yet recruiting University of Chicago Phase 2 2022-07-01 The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on established outcome measures of BPD symptoms that have been used in prior studies).
NCT05890768 ↗ Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine Recruiting University of New Mexico Phase 4 2023-05-11 This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients. Baseline glutamate and dopamine brain scans, and symptom severity measures will be collected, followed by repeated measures at 6 weeks. Half of the early psychosis patients will be treated with lumateperone, half with risperidone. Healthy control subejcts will also be examined once.
NCT06174116 ↗ Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia Recruiting Intra-Cellular Therapies, Inc. Phase 4 2024-04-02 The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for 12 weeks, in addition to their regularly prescribed clozapine. During their participation, patients will answer questions about their psychiatric and daily functioning, have blood drawn, and have their body composition analyzed (similar to stepping on a scale).
NCT06174116 ↗ Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia Recruiting University of Massachusetts, Worcester Phase 4 2024-04-02 The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone (Caplyta) or a placebo for 12 weeks, in addition to their regularly prescribed clozapine. During their participation, patients will answer questions about their psychiatric and daily functioning, have blood drawn, and have their body composition analyzed (similar to stepping on a scale).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CAPLYTA

Condition Name

Condition Name for CAPLYTA
Intervention Trials
Borderline Personality Disorder 1
Psychosis 1
Schizo Affective Disorder 1
Schizophrenia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CAPLYTA
Intervention Trials
Psychotic Disorders 2
Mental Disorders 1
Personality Disorders 1
Borderline Personality Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CAPLYTA

Trials by Country

Trials by Country for CAPLYTA
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CAPLYTA
Location Trials
Massachusetts 1
New Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CAPLYTA

Clinical Trial Phase

Clinical Trial Phase for CAPLYTA
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CAPLYTA
Clinical Trial Phase Trials
Recruiting 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CAPLYTA

Sponsor Name

Sponsor Name for CAPLYTA
Sponsor Trials
Intra-Cellular Therapies, Inc. 2
University of Chicago 1
University of New Mexico 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CAPLYTA
Sponsor Trials
Other 3
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.